Roche Holding AG (RHHBF) on Decifer

Decifer ranks RHHBF number 204 of 270 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 17% and it turns most of its profit into real cash.
• Revenue is expected to grow about 4% a year, profits grew 56% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• 17% returns and 56% profit growth provide durability but expected 4% revenue growth and no funded role limit the upside.

The current read

The evidence on RHHBF lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Genomic Medicine & Precision Diagnostics: The collapsing cost of DNA/RNA sequencing and validation of genomic classifiers is moving clinical practice toward routine molecular diagnostics and companion testing.

Read the full RHHBF research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.